The concept of bacterial interference, both passive and active, embodies the use of bacteria of low virulence to compete with and protect against colonization and infection by disease-causing organisms. Passive bacterial interference is achieved when naturally present commensal bacteria help defend against host infection by pathogenic organisms. Examples of bodily sites that are protected by normal flora include the skin, oral cavity, upper respiratory tract, vagina, bladder, and bowels. In instances where natural bacterial flora may not afford adequate resistance to colonization and/or infection, active bacterial interference can be useful by intentionally administering into the human body bacteria of low virulence that could replace pathogens. The potential benefit of bacterial interference in preventing infection has been explored with variable success in differently designed studies of various conditions (including urinary tract infection, vaginosis, burn, and antibiotic-associated colitis) by using different agents (including Escherichia coli, Lactobacillus species, Streptomyces species, and skin flora) [1] [2] [3] .
Not only is urinary tract infection (UTI) the most common healthcare-acquired infection, but it also accounts for 8-11 million patient visits each year in the United States [4] . Because the risk-benefit analysis does not favor the general use of antimicrobial-based measures to prevent UTI, there exists a pressing need to explore the role of nonantimicrobial preventive approaches. To eliminate uropathogens, a number of studies have aimed at deliberate colonization of the bladder with bacteria of low virulence. This approach is supported by the fact that treatment of asymptomatic bacteriuria is not only contraindicated in general, but can also lead to emergence of uropathogens and development of symptomatic infection [5] [6] [7] . This review focuses on the role of bacterial interference in preventing UTI by using E. coli in patients with neurogenic/dysfunctional bladder or Lactobacillus species mostly in healthy women. It assesses the role of different agents of bacterial interference, explores the potential mechanisms of action, summarizes the results of clinical studies, compares different bacterial applications, and highlights future research.
AGENTS OF BACTERIAL INTERFERENCE
The 2 bacterial organisms that have been clinically tested as agents of bacterial interference for specifically preventing UTI include E. coli (E. coli strains 83792 and HU2117) and a variety of Lactobacillus species (mostly L. crispatus CTV05, L. casei var rhamnosus GR1 and GG, and L. fermentum B54).
Escherichia coli
Bacterial interference utilizing nonpathogenic E. coli for prevention of UTI was originally established by using E. coli 83972, an organism that had caused asymptomatic bacteriuria for 3 years in a young girl without altering renal function [8] . Although E. coli 83972 has not been reported to cause symptomatic UTI and usually does not express P fimbriae, it contains the full chromosomal pap gene that encodes P fimbriae [9, 10] . Escherichia coli HU2117 is a genetically engineered strain created from wild-type E. coli 83972 that has an 800-base pair deletion mutation in the chromosomal papG gene [9] . As a result, it cannot make functional P fimbriae, which are associated with pyelonephritis and bacteremia. Based on in vitro data, E. coli HU2117 seems to be indistinguishable from E. coli 83972 with respect to bladder colonization and ability to prevent biofilm formation on urinary catheters by uropathogens [11] .
Lactobacillus species
Lactobacilli are the dominant vaginal flora and possess antimicrobial properties that regulate other urogenital microbes. Although a variety of Lactobacillus species have been reported as healthy vaginal flora, L. crispatus, L. gasseri, L. inners, and L. jensenii appear to be most common [12] . Lactobacillus casei var rhamnosus strains have been evaluated as potential probiotic agents in the vagina but have not been reported as part of normal vaginal flora [12] . Since high concentrations of Lactobacillus species in the vagina correlate with a lower rate of UTI, the use of Lactobacillus-containing probiotics to restore commensal vaginal flora has been proposed for the treatment and prophylaxis of bacterial urogenital infections [4, 13] . In most occasions, however, Lactobacillus species is intentionally introduced into the human body for reasons other than prevention of UTI, including control of bacterial vaginosis and regulation of bowel flora. Because the potential for preventing UTI using bacterial interference by probiotic Lactobacillus is based primarily on the displacement of potential uropathogens from the vagina, this approach is utilized exclusively in women. An attempt to colonize the urethra or bladder directly through intravesicle inoculation with Lactobacillus was unsuccessful in men [13] . Figure 1 displays a humorous scientific version of potential mechanisms of bacterial interference. Mechanisms of action, listed in a clockwise fashion starting at the right upper corner, include competition for nutrients, production of antibacterial agents (including bacteriocins, antiseptics, and acidic substances), competition for attachment sites, regulation of gene expression, immunomodulation, and biofilm disruption. Coaggregation of organisms could also enhance the goal of bacterial interference. Escherichia coli and Lactobacillus species share some but not all mechanisms of bacterial interference.
MECHANISMS OF ACTION

Escherichia coli 83972
Competition for Nutrients It has been suggested that the primary mechanism for bacterial interference by E. coli 83972 is competition with other bacteria for nutrients [14] . This concept was based on the observation that E. coli 83972 grew faster than several tested uropathogenic E. coli strains and significantly outperformed 1 uropathogenic E. coli strain in cocultures, both in vitro and in a murine bladder colonization model. However, human colonization trials indicate that E. coli 83972 may not eliminate other bacteria from the urine after relatively few generations. During long-term colonization in human subjects, E. coli 83972 colonized the bladder along with other bacteria that coexisted at the same or lower concentration [15] [16] [17] . In some instances bladder cocolonization along with E. coli 83972 was transient, whereas in others cocolonizers persisted for extended periods of time in the absence of symptomatic UTI.
Bacteriocin Production
Bacteriocins, including colicins and microcins, are antibiotic proteins produced by many species of bacteria that kill susceptible bacteria of the same species. An in vitro study showed that coating a urinary catheter with a colicin-producing strain of E. coli completely prevented catheter colonization by a susceptible clinical isolate but not by a colicin-resistant isolate [18] . Escherichia coli 83972 does not produce detectable levels of bacteriocin when studied in vitro, but genomic studies suggest that it has the genetic potential for expressing 3 microcins, namely, H47, M, and B17 [19] .
Competition for Attachment Sites
A recent report suggested that attachment of probiotic E. coli Nissle to host tissue may prevent attachment of pathogenic bacteria [20] . Although E. coli Nissle has been used for prevention of various intestinal diseases, its use as a probiotic agent for prevention of UTI has been proposed but not evaluated experimentally [21] . The role of specific adherence in stable colonization of the human bladder by E. coli 83972 has been examined in several studies. In support of the attachment-competition model, E. coli 83972 was reportedly capable of adherence, albeit at a moderate level, to exfoliated uroepithelial cells and urinary catheters [22] . However, others suggested that specific bacterial adherence was not required for bladder colonization [8] . A subsequent report indicated that P fimbriae were not required for bladder colonization since a P negative null mutant of E. coli 83972 exhibited the same colonization attributes as wild type [23] . Escherichia coli 83972 derivatives that contain P-fimbrial genes on a plasmid exhibited enhanced early colonization of the bladder but the P adherence phenotype was lost shortly thereafter [14] . Genes for other E. coli fimbriae classes associated with specific adherence in the urinary tract, including type 1, type 1c, S, Dr, and M adhesions, are either not present in E. coli 83972 or are defective [19, 24] . Recent DNA sequence analysis of E. coli 83972 revealed a fimbrial gene cluster similar to an uroepithelial cell adhesin called Uca that is found in Proteus mirabilis [25] .
Biofilm Prevention
Escherichia coli 83972 shows a low but detectable level of adherence to silicone urinary catheters. Pretreatment of urinary catheters with E. coli 83972 reportedly prevented colonization of the catheters in vitro after challenge with a variety of uropathogens [26] . These results suggest that presence of an E. coli 83972 biofilm interferes with subsequent colonization of catheters by pathogenic bacteria. Enhancement of the capacity of E. coli 83972 to form a biofilm on catheter material by adding type 1 fimbriae was associated with improvement in bacterial interference in a dose-responsive manner [27] . Although these findings are consistent with the hypothesis that E. coli 83972 biofilm presents a physical barrier to attachment by pathogenic bacteria, other interpretations remain possible.
Lactobacillus species
The topic of potential mechanisms for the therapeutic effect of probiotic Lactobacillus at sites other than the urinary tract has been the subject of several recent reviews [28] [29] [30] . Many of the mechanisms that have been suggested to spear head the activity of Lactobacillus probiotics against organisms and infections outside the urinary tract may also apply to prevention of UTI. Potential mechanisms by which Lactobacillus species cause bacterial interference are described below.
Immunomodulation
Recent studies suggest that modulation of host immune functions may contribute to the therapeutic effect of probiotic Lactobacillus [31] . The authors of a 2-patient pilot study suggested that immunomodulation by Lactobacillus-induced downregulation of proinflammatory cytokines such as tumor necrosis factor α, interleukin 6, interleukin 8, interleukin 10, and interleukin 12 ( p70) may be beneficial [32] . However, factors that were not assessed in this study, such as the presence/absence of bacteriuria during the 90-day trial period, could have confounded the interpretation of results.
Gene Regulation
Increasing evidence indicates that bacterial products from probiotic Lactobacillus may induce downregulation in expression of virulence factors [30, 33] . Spent culture supernatants from probiotic Lactobacillus reportedly downregulated the promoter activity of E. coli type 1 and P fimbriae genes [34] . Type 1 and P fimbriae are associated with urinary tract colonization and infection, but their role in vaginal colonization has not been investigated. The extent to which Lactobacillus products can prevent specific adherence of uropathogens to the vaginal epithelium or suppress subsequent expression of fimbrial genes after the bacteria migrate to the urinary tract is unknown. Type 1 fimbriae also contribute to colonization of urinary catheters [27] . Additional studies are required to show whether probiotic Lactobacillus can suppress bacterial colonization of urinary catheters in vivo by use of a gene regulation mechanism.
Biofilm Prevention
Biofilms formed by pathogenic bacteria can facilitate bacterial colonization of tissues and complicate management of established infection. It is theoretically possible that introduction of nonpathogenic organisms could displace biofilmembedded pathogens in the vagina and, subsequently, prevent UTI. A recent in vitro study showed that application of probiotic L. rhamnosis GR-1 to biofilms formed in vitro by a uropathogenic E. coli strain interfered with the integrity of the biofilm and caused significant killing of E. coli [35] .
Production of Antibacterial Agents
The mechanism by which Lactobacillus species kill bacterial pathogens could be multifactorial and may include production of bacteriocin-like molecules, hydrogen peroxide, and lactic acid. In a dose-and pH-dependent manner, lactic acid, hydrogen peroxide, and spent culture supernatants from urogenital probiotic strains L. casei var rhamnosus GR-1 and L. reuteri RC-14 all strongly inhibited growth of uropathogenic E. coli strains and increased the promotor activity of outer membrane proteins A and X ( porins that are normally upregulated in response to stress by uropathogens) [34] . That same study also showed that lactic acid and Lactobacillus spent culture supernatants could downregulate the promoter activity of the major subunits of type 1 and P fimbriae virulence factors. In another study, hydrogen peroxide acted individually and in cooperation with lactic acid to kill uropathogenic E. coli [36] .
Other Mechanisms
Probiotic mechanisms for vaginal Lactobacilli that prevent colonization by vaginal pathogens may also prevent vaginal colonization with uropathogens. These include bacteriocin production and aggregation. Whereas both mechanisms have been associated with probiotic Lactobacillus at other bodily sites, their role in UTI prophylaxis has not been investigated.
CLINICAL TRIALS
The attributes and results of important clinical trials of bacterial interference using E. coli [9, 10, 15, 16, [37] [38] [39] or Lactobacillus species [40] [41] [42] [43] [44] [45] are summarized in Tables 1 and 2 , respectively. Neither E. coli nor Lactobacillus species have reportedly caused symptomatic UTI. Not unexpectedly, all listed studies were relatively small in size (≤100 patients), particularly the E. coli-based trials as they required either direct bladder inoculation of nonpathogenic bacteria twice a day for 3 consecutive days (1 set of inoculation) up to 3 sets, or immersion of a bladder catheter in a bacterial suspension of nonpathogenic E. coli for 24 hours before inserting the E. coli-coated catheter into the bladder. As a corollary, the finding of an insignificant trend of efficacy in some studies could be attributed to their insufficient power. Although all listed trials were pilot studies intended to generate preliminary data before embarking on pivotal comparative trials, some trials significantly reduced the incidence of UTI by several-fold. Whereas many listed studies were randomized, placebo-controlled, doubleblind studies, others suffered from a suboptimal single-arm design that dictated comparison of generated data to historic control.
Recent Infectious Diseases Society of America guidelines on UTI [46] utilized a systematic weighting of the quality of evidence that can be strong (I), moderate (II), or weak (III). Although this review is not intended to provide clinical recommendations, it would be reasonable to use that system to partially assess the quality of evidence emanating from particular subcategories of studies that share the same interfering agent and mode of intervention. Although 2 of the 5 studies that assessed bladder inoculation by E. coli were randomized controlled and demonstrated significant efficacy [9, 15] , the small number of evaluable patients disallows a high quality of evidence. The 2 studies [38, 39] that assessed insertion of an E. coli-treated catheter were open-label and very small, and, therefore, generated evidence that would be of moderate quality at best. Although all 4 randomized controlled studies [40, [43] [44] [45] that evaluated Lactobacillus-containing vaginal suppository indicated some level of efficacy, they were not optimally conducted, thereby minimizing the quality of evidence to moderate. The single randomized controlled trial [42] of an oral drink that contains Lactobacillus is the largest published study on bacterial interference, but other studies need to be done before establishing a high quality of evidence. Table 3 compares the attributes of E. coli-based vs Lactobacillus-based applications. In contrast to E. coli that could be inoculated into the bladder either directly or via a catheter covered by a biofilm containing E. coli, Lactobacillus species could be introduced in the form of a vaginal suppository or an oral drink. Because the protective effect by nonpathogenic E. coli is based on controlling pathogens at the site of infection, the achieved urinary concentrations of nonpathogenic strains of E. coli are usually the same or higher than those of other bacteria that may coexist in the bladder [15] . A different mode of action, control of the source of pathogens, applies to Lactobacillus species which replace virulent vaginal flora that could migrate from the vagina to the bladder and cause symptomatic UTI in women. Although intentional bladder colonization with nonpathogenic E. coli strains has been reported to cause local inflammatory symptoms (bladder irritability) and signs ( pyuria), we know of no similar issues in patients who receive Lactobacillus-containing supplements. There is no evidence that bacterial interference adversely affects kidney function. Notwithstanding the impact of differences in study design and size on outcome, the protective efficacy of intentional bladder colonization with nonpathogenic E. coli strains seems to be more consistent than that afforded by introducing probiotic Lactobacillus. On the other hand, the practicality and cost of intervention favor the Lactobacillus-based approach, which is less invasive and expensive than bladder inoculation with nonpathogenic E. coli strains. As compared to direct bladder inoculation, the insertion of E. coli-coated bladder catheter is more practical and less costly. Routine administration of systemic antibiotics before bladder inoculation with E. coli 83972 or HU2117 with the aim of reducing the urinary concentration of preexisting bacteria not only augments the likelihood that the bladder will become colonized by these nonpathogenic strains, but also could contribute to higher urinary concentrations of inoculated E. coli strains vs co-colonizing bacteria [9, 15] . Systemic antibiotics, however, are inconsistently given in patients receiving probiotic Lactobacillus. Although bacterial interference is generally intended to improve the quality of life of patients who suffer from recurrent episodes of symptomatic UTI, these 2 particular approaches of bacterial interference apply to distinctly different patient populations; whereas nonpathogenic strains of E. coli have been utilized to prevent symptomatic UTI in patients with neurogenic/dysfunctional bladder (including those with spinal cord injury), the Lactobacillusbased strategy is applied mostly in healthy women. Finally, the use of nonpathogenic strains of E. coli for prevention of UTI requires approval from the Food and Drug Administration (FDA) through an Investigational New Drug application. Although current use of probiotic Lactobacillus for prevention or treatment of infection also requires FDA approval, it is, unfortunately, sometimes used as a "dietary supplement" to escape the stringent FDA evaluation.
COMPARISON OF BACTERIAL APPLICATIONS
FUTURE DIRECTIONS
No person is immune from developing UTI. In general, about a third of women have their first UTI by the age of 24 years, and more than a quarter of adult females with a first episode of UTI will have a recurrence [4] . The statistics are even worse in patients who suffer from neurogenic bladder, especially those with spinal cord injury in whom UTI is the most common infectious condition [16] . Preliminary data from the summarized pilot studies are promising, but in and by themselves are not sufficient to establish new standard-of-care practices. Although clinically protective against UTI, limitations to wide-scale implementation of bacterial interference using nonpathogenic strains of E. coli in patients with neurogenic bladder include relative impracticality and high cost of direct bladder inoculation, the possibility that nonpathogenic strains of E. coli could be inflammatory in patients with sensate bladder, and the small size of completed pilot studies. That is why we plan to conduct a randomized, placebo-controlled, double-blinded, multicenter trial that assesses the efficacy, safety, and economic implications of inserting a bladder catheter that contains a biofilm of nonpathogenic E. coli. As to Lactobacillus species, further work needs to be done to document the stability of probiotic products, assess the effects of specific strains, and explore the impact of probiotic concentration on efficacy. 
